“Emergence of AI, Liquid Biopsy, and Multi-Cancer Early Detection (MCED) as Game-Changing Trends”
- One prominent trend in the global cancer diagnostics market is the rapid integration of artificial intelligence (AI), liquid biopsy, and multi-cancer early detection (MCED) technologies into mainstream diagnostic practices
- These innovations are reshaping the diagnostic landscape by enabling earlier, more precise, and less invasive detection of multiple cancer types from a single sample
- For instance, liquid biopsy platforms can detect circulating tumor DNA (ctDNA) in blood, offering real-time insights into tumor mutations without the need for surgical biopsy, while AI-powered imaging tools are enhancing diagnostic accuracy in radiology and pathology
- These trends are driving a shift toward personalized medicine, improving clinical decision-making, and expanding the potential for large-scale cancer screening, particularly in asymptomatic populations
